MEDI 6012

Drug Profile

MEDI 6012

Alternative Names: ACP-501; MEDI-6012; recombinant-lecithin-cholesterol-acyltransferase; rhLCAT

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator AlphaCore Pharma
  • Developer AstraZeneca; MedImmune
  • Class Acyltransferases; Antianaemics; Antihyperlipidaemics; Enzymes; Recombinant proteins
  • Mechanism of Action Apolipoprotein A I stimulants; Cholesterol modulators; Transferase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lecithin acyltransferase deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute coronary syndromes; Atherosclerosis; Coronary artery disease
  • Phase I Arterial thrombosis
  • Preclinical Adrenal gland disorders; Anaemia; Lecithin acyltransferase deficiency; Sickle cell anaemia

Most Recent Events

  • 01 Jan 2017 Phase-II clinical trials in Atherosclerosis (In the elderly) in USA (IV) (NCT03004638)
  • 22 Dec 2016 MedImmune plans a phase IIa trial for Atherosclerosis (Adjunctive treatment, In the elderly) in USA (NCT03004638)
  • 01 Nov 2016 MedImmune completes a phase II trial in Coronary artery disease (In adults, In the elderly) in USA (IV) (NCT02601560)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top